It has been reported that 13%–65% of patients do not know whether their tumor is hormone sensitive, 34%–70% are unaware of their HER2 status, and 28%–49% do not know their disease stage.11, 12, 13, 14, 15, 16, 17, 18. This evidence concerns the gene ERBB2 and neoplasm.